Bipolar Disorder

Houston, TX

21 Bipolar Disorder Trials near Houston, TX

Power is an online platform that helps thousands of Bipolar Disorder patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

KarXT for Bipolar Disorder

Houston, Texas
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, inpatient study in participants with bipolar disorder experiencing an acute episode of mania or mania with mixed features. The primary objective of the study is to evaluate the efficacy of KarXT compared to placebo in treating symptoms of mania during a 3-week inpatient period. The duration of the study including screening, the double-blind inpatient treatment period and safety-follow-up is no more than seven weeks.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65

274 Participants Needed

KarXT for Bipolar Disorder

Houston, Texas
This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to evaluate the long-term safety and tolerability of KarXT in the treatment of participants with mania or mania with mixed features associated with BP-I.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65

450 Participants Needed

RAP-219 for Bipolar Disorder

Houston, Texas
This is a clinical research study for an investigational drug called RAP-219 in participants with bipolar I disorder. This study is being conducted to determine if RAP-219 is safe and effective in participants experiencing mania associated with bipolar I disorder.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

224 Participants Needed

MST for Bipolar Disorder

Houston, Texas
The purpose of this study is to compare the efficacy and side effects magnetic seizure therapy (MST) and electroconvulsive therapy (ECT) in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:22 - 85

60 Participants Needed

Lumateperone for Pediatric Bipolar Depression

Houston, Texas
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:10 - 17

384 Participants Needed

Palmitoylethanolamide for Bipolar Depression

Houston, Texas
The purpose of this study is to o evaluate the antidepressant efficacy of the PEA in Bipolar Depression and the association between antidepressant response with endogenous cannabinoids and cytokine levels

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

50 Participants Needed

Deep Brain Stimulation for Bipolar Disorder

Houston, Texas
This study is only enrolling at Baylor College of Medicine. The other research locations listed serve to support data analysis only. This research study is to investigate the use of technology called Deep Brain Stimulation (DBS) to potentially improve Treatment-Resistant Bipolar Depression (TRBD) symptoms in patients with severe cases. DBS involves the surgical implantation of leads and electrodes into specific areas of the brain, which are thought to influence the disease. A pack implanted in the chest, called the neurotransmitter, keeps the electrical current coursing to the brain through a wire that connects the neurotransmitter and electrodes. It is believed DBS may restore balance to dysfunctional brain circuitry implicated in TRBD. The goal of this study is to enhance current approaches to DBS targeting in the brain and to use a novel approach to find a better and more reliable system for TRBD treatment. Its important for participants to understand that this is an investigational study where there could be a lack of effectiveness in improving TRBD symptoms. There may be no directly benefit from taking part in this study. This study is expected to last 20 months and involves 3 main steps. 1. Medical, psychiatric, and cognitive evaluations. 2. Implantation of a brain stimulation system. 3. Follow up after implantation of device, including programming, recording, and psychiatric testing. There are risks and benefits to this study which need to be considered when deciding to participate or not. Some of the risks are from surgery, the DBS device and programming, the tests involved, and potential loss of confidentiality, as well as other unknown risks. Some of the more serious risks involved in this study and the percentage that they occur: 1. Bleeding inside the Brain (1 to 2 percent). 2. Infection from the procedures (3 percent) 3. Seizure caused from the procedures (1.2 percent) However, the benefit of this study is that it may help relieve or decrease TRBD symptoms. This form of treatment has shown to reduce symptom severity in other cases. This could potentially improve quality of life and activities in daily routines. There is also a potential benefit to society in that the data the investigators will obtain from this study may help increase the understanding of the mechanisms underlying TRBD symptoms, as well as enhanced Deep Brain Stimulation techniques. Study participation is expected to last 20 months from the time the DBS device is activated and should include approximately 23 visits. These visits also include 8 separate, 24 hour stays at the Menninger NeuroBehvaioral Monitoring Unit (NBU). These 24-hour sessions will occur at multiple points throughout the study (1 week prior to surgery, the week preceding device activation, the week following activation, then after 2 weeks, 4 weeks, 6 months, 9 months, and 12 months). Participants will need to stay locally for the week of the NBU stay (typically Monday through Friday). Study visits will include clinician administered assessments and questionnaires, subject reported assessments, neuropsychological testing, and mobile behavioral assessments which will occur around 23 visits over the course of 20 months.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:22 - 64

10 Participants Needed

Multiple Medications for Bipolar Depression

Houston, Texas
This trial is testing four different medications to find the best treatment for adults with bipolar disorder type 1 who are currently depressed. The medications work by balancing brain chemicals that affect mood. The goal is to help patients recover from depression and stay well.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 4

2726 Participants Needed

Psilocybin for Bipolar Disorder

Houston, Texas
The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:25 - 70

10 Participants Needed

Cariprazine for Pediatric Schizophrenia

Houston, Texas
This trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:5 - 17

310 Participants Needed

NRX-101 for Bipolar Depression

Houston, Texas
This trial tests a two-step treatment for adults with severe bipolar depression and suicidal thoughts. It starts with a quick-acting ketamine dose followed by an oral medication to maintain improvement. The goal is to see if this approach is better than using lurasidone alone. Ketamine has been shown to rapidly reduce depressive and suicidal symptoms in both unipolar and bipolar depression.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:18 - 65

72 Participants Needed

Lumateperone for Schizophrenia and Bipolar Disorder

Houston, Texas
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:5 - 17

500 Participants Needed

VNS for Bipolar Depression

Houston, Texas
This trial is testing whether VNS Therapy, which sends electrical impulses to the vagus nerve, can reduce depression symptoms in patients who haven't responded to other treatments. The study will observe the effects of VNS therapy over a year. Vagus nerve stimulation (VNS) is a recognized treatment for severe treatment-resistant depression and has shown promising results.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

6800 Participants Needed

tDCS for Bipolar Disorder

Houston, Texas
This trial is testing whether a gentle electrical stimulation of the brain can help people who struggle to feel pleasure. The treatment targets specific brain pathways involved in reward and pleasure. Researchers want to see if this method can improve symptoms by activating these pathways.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 50

45 Participants Needed

ALTO-100 for Bipolar Depression

Houston, Texas
The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used adjunctively to a mood stabilizer, related to patient characteristics. Additionally, safety, tolerability, and efficacy will be assessed in a subsequent open label treatment period.

Trial Details

Trial Status:Recruiting

200 Participants Needed

Stem Cell Therapy for Bipolar Depression

Houston, Texas
This trial uses special cells from donated bone marrow to treat patients with bipolar depression who haven't responded to standard treatments. The cells may help by reducing inflammation and promoting brain healing. This approach has shown promise in preventing depression and anxiety in animal studies.
Stay on current meds

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65

30 Participants Needed

NMRA-335140 for Bipolar Depression

Houston, Texas
This trial is testing a new medication called NMRA-335140 to see if it can help adults with Bipolar II disorder who are experiencing major depression. The medication aims to improve mood and reduce feelings of depression.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 65

60 Participants Needed

RFA Knife for POEM in Esophageal Disorders

Houston, Texas
This trial is testing a new surgical tool called the Speedboat-RSD knife for patients with esophageal muscle issues. The tool aims to make the procedure faster and less painful by combining cutting and bleeding control in one device. The Speedboat-RS2 (Creo-Medical, UK) is a novel device which has shown promising results for similar procedures.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

105 Participants Needed

Cariprazine for Bipolar Disorder in Youth

Houston, Texas
This trial is testing the safety and effectiveness of Cariprazine for treating depressive episodes in children and teenagers with bipolar I disorder. The goal is to find out if Cariprazine can help young people with this condition. Cariprazine is an atypical antipsychotic recently approved for the treatment of depressive episodes in adults with bipolar I disorder.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Age:10 - 17

380 Participants Needed

ABBV-932 for Bipolar Disorder

Richmond, Texas
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. The purpose of this study is to assess how safe and effective ABBV-932 is in treating participants with depressive episodes associated with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Participants with bipolar I or II disorder who are currently experiencing a depressive episode will enter the study and be treated with open-label ABBV-932. Approximately 200 adult participants with bipolar I or II disorder will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 for a 26-week treatment period. The treatment period will be followed by a safety follow-up (SFU) period of 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regularly scheduled visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

200 Participants Needed

Why Other Patients Applied

"I really would love to be normal. A functioning part of society. It is very hard to hold a job with this condition. I need to be steady. I do NOT like my current meds or ones I've tried before, so new therapies are of interest to me. "

EC
Bipolar Disorder PatientAge: 42

"My mania is under control but I still have no way of handling depression. I've been looking into new treatments and I would be so grateful to be able to try one of the latest research treatments. Even if it fails: it's worth a shot, better than giving up. I'm a bit at wit's end."

PW
Bipolar Disorder PatientAge: 30

"I have suffered from different mental health issues and have not had very good luck with finding what works best for me. My mental illness is seriously hurting my marriage and home life... I've been reading about new research treatments and think that they might work better than traditional treatments. Excited to try."

QQ
Bipolar Disorder PatientAge: 43

"I've been experiencing bipolar depression since I was a teenager and have tried many treatments that have not helped: SSRIs (Prozac), Wellbutrin, talk therapy. None worked. I've heard great things about ketamine therapy and would really like to try it. I'd like to access it through a clinical trial."

FM
Bipolar Disorder PatientAge: 38

"I am hoping to find some medication to finally help me & my mood disorder. I have tried multiple other options over the years but without much luck of controlling the depression or mania."

MM
Bipolar Disorder PatientAge: 40

ABBV-932 for Bipolar Disorder

Richmond, Texas
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how safe and effective ABBV-932 is in treating participants with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Study doctors put participants in 1 of 4 groups, called treatment arms. There is a 1 in 4 chance that a participant will be assigned to placebo. Around 160 adult participants with bipolar I or II disorder will be enrolled in approximately 40 sites worldwide. Participants will receive oral capsules of ABBV-932 or matching placebo once daily for 6 weeks. The treatment period will be followed by a safety follow-up (SFU) period for 4 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Trial Details

Trial Status:Recruiting
Age:18 - 65

160 Participants Needed

Know someone looking for new options? Spread the word

Match to a Trial